NASDAQ
MRNA

Moderna Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Moderna Inc Stock Price

Vitals

Today's Low:
$103.5325
Today's High:
$106.165
Open Price:
$105.37
52W Low:
$95.02
52W High:
$217.25
Prev. Close:
$105.8
Volume:
2245287

Company Statistics

Market Cap.:
$40.27 billion
Book Value:
44.486
Revenue TTM:
$10.65 billion
Operating Margin TTM:
4.82%
Gross Profit TTM:
$10.55 billion
Profit Margin:
11.33%
Return on Assets TTM:
1.34%
Return on Equity TTM:
6.91%

Company Profile

Moderna Inc had its IPO on 2018-12-07 under the ticker symbol MRNA.

The company operates in the Healthcare sector and Biotechnology industry. Moderna Inc has a staff strength of 3,900 employees.

Stock update

Shares of Moderna Inc opened at $105.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $103.53 - $106.17, and closed at $105.24.

This is a -0.53% slip from the previous day's closing price.

A total volume of 2,245,287 shares were traded at the close of the day’s session.

In the last one week, shares of Moderna Inc have slipped by -6.5%.

Moderna Inc's Key Ratios

Moderna Inc has a market cap of $40.27 billion, indicating a price to book ratio of 4.4617 and a price to sales ratio of 3.7224.

In the last 12-months Moderna Inc’s revenue was $10.65 billion with a gross profit of $10.55 billion and an EBITDA of $876 million. The EBITDA ratio measures Moderna Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Moderna Inc’s operating margin was 4.82% while its return on assets stood at 1.34% with a return of equity of 6.91%.

In Q2, Moderna Inc’s quarterly earnings growth was a negative -97.8% while revenue growth was a negative 92.8%.

Moderna Inc’s PE and PEG Ratio

Forward PE
32.4675
Trailing PE
37.6513
PEG
0

Its diluted EPS in the last 12-months stands at $2.81 per share while it has a forward price to earnings multiple of 32.4675 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Moderna Inc’s profitability.

Moderna Inc stock is trading at a EV to sales ratio of 3.5399 and a EV to EBITDA ratio of 5.3418. Its price to sales ratio in the trailing 12-months stood at 3.7224.

Moderna Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$21.88 billion
Total Liabilities
$3.12 billion
Operating Cash Flow
$1.94 billion
Capital Expenditure
$234 million
Dividend Payout Ratio
0%

Moderna Inc ended 2024 with $21.88 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $21.88 billion while shareholder equity stood at $16.95 billion.

Moderna Inc ended 2024 with $0 in deferred long-term liabilities, $3.12 billion in other current liabilities, in common stock, $17.02 billion in retained earnings and $52.00 million in goodwill. Its cash balance stood at $3.80 billion and cash and short-term investments were $8.46 billion. The company’s total short-term debt was $221,000,000 while long-term debt stood at $0.

Moderna Inc’s total current assets stands at $10.60 billion while long-term investments were $6.11 billion and short-term investments were $4.66 billion. Its net receivables were $232.00 million compared to accounts payable of $310.00 million and inventory worth $715.00 million.

In 2024, Moderna Inc's operating cash flow was $1.94 billion while its capital expenditure stood at $234 million.

Comparatively, Moderna Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$105.24
52-Week High
$217.25
52-Week Low
$95.02
Analyst Target Price
$181.47

Moderna Inc stock is currently trading at $105.24 per share. It touched a 52-week high of $217.25 and a 52-week low of $217.25. Analysts tracking the stock have a 12-month average target price of $181.47.

Its 50-day moving average was $113.55 and 200-day moving average was $145.02 The short ratio stood at 4.38 indicating a short percent outstanding of 0%.

Around 968.5% of the company’s stock are held by insiders while 6948% are held by institutions.

Frequently Asked Questions About Moderna Inc

The stock symbol (also called stock or share ticker) of Moderna Inc is MRNA

The IPO of Moderna Inc took place on 2018-12-07

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$10.13
-0.89
-8.08%
$1720
-35.3
-2.01%
$36.45
-0.23
-0.63%
$459.7
-1.1
-0.24%
$766.2
-34.25
-4.28%
MUKTA ARTS LTD. (MUKTAARTS)
$60.41
-1.45
-2.34%
$12.14
-1.1
-8.31%
$724.55
-47.2
-6.12%
$10.18
0
-3.24%
$21.12
0.2
+0.96%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Address

200 Technology Square, Cambridge, MA, United States, 02139